Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial
Lancet Gastroenterol Hepatol. 2025;10:210–221. doi: 10.1016/S2468-1253(24)00386-8.
Sands et al. evaluated tamuzimod, a selective sphingosine 1-phosphate receptor 1 modulator, in patients with moderately-to-severely active UC. At Week 13, clinical remission (defined as an MMS stool frequency subscore of ≤1, rectal bleeding subscore of 0, and endoscopic subscore ≤1, excluding friability) was achieved by 28% and 24% of patients receiving tamuzimod 60 mg and 30 mg, respectively, compared with 11% in the placebo group. The treatment was well tolerated; most AEs were mild or moderate.
This phase 2, randomised, placebo-controlled trial enrolled 213 patients across 15 countries. Participants with inadequate response to approved UC therapies received tamuzimod or placebo for 13 weeks. The findings support further development of tamuzimod for UC treatment.
Keywords:
